Multiple myeloma (MM) is a malignancy characterized by a very slow proliferation of malignant plasma cells leading to their accumulation within the bone marrow. This suggests that resistance to apoptosis may play a critical role both in the pathogenesis and resistance to treatment of MM. Bcl-2 is a key protein for the regulation of apoptosis. However, it has been shown that this protein also regulates the state of proliferation. In the current study, we show that malignant plasma cells from both the bone marrow and peripheral blood express high levels of Bcl-2 and are slowly proliferating cells. In contrast, myeloma cells from extramedullary sites (ie pleural effusion, ascitis, mammary and gastric plasmacytoma) express Bcl-2 weakly while being highly proliferative. Normal non-dividing bone marrow plasma cells express high levels of Bcl-2 protein. In contrast, four highly proliferative reactive plasmacytosis express weak levels of Bcl-2. We conclude that there is an inverse correlation between Bcl-2 expression and the proliferation rate of both normal and malignant plasma cells. These data may be explained by the double function of Bcl-2, ie its well known function as an anti-apoptotic molecule and its intriguing function as an inhibitory molecule of cell proliferation.
Introduction
Multiple myeloma (MM) is a malignancy characterized by a very slow proliferation of malignant plasma cells leading to their accumulation within the bone marrow but by their late and high proliferation in extramedullary sites. This accumulation of malignant plasma cells within the bone marrow suggests that resistance to apoptosis may play a critical role in the pathogenesis of MM.
Apoptosis is essential for normal development, lymphoid maturation, homeostasis and defense against viral infections. Bcl-2 was first identified in the translocation (14;18) observed in follicular lymphoma. The Bcl-2 protein has been shown to confer resistance to apoptosis induced in a variety of systems such as growth factor withdrawal, cross link of cell surface receptors, oncogene activation, steroids or DNA damage. Bclx L a close homologue to Bcl-2 is also able to promote cell survival. 2 Both proteins are thought to protect from apoptosis by heterodimerizing with proapoptotic members of the Bcl-2 family, Bax and Bad. 2 They also act by preventing both the release of cytochrome C from mitochondria and the activation of caspases leading to the final steps of apoptosis. 3 Furthermore, there are now several reports consistent with the notion that Bcl-2 is involved in the regulation of cell cycle leading to a cell cycle inhibitory effect. [4] [5] [6] [7] [8] Different mechanisms by which Bcl-2 acts on the cell cycle have been proposed. 4, 5 On the one hand, some findings suggest that overexpression of Bcl-2 inhibits cell cycle progression by lengthening the G1 phase and consequently affects the growth rate of cell lines. On the other hand some other reports indicate that Bcl-2 favors dormancy over the cycling state. [6] [7] [8] The influence of Bcl-2 on the cell cycle is in agreement with the regulation of Bcl-2 during activation and differentiation of B cells. Indeed, in the B cell compartment, Bcl-2 is highly regulated during activation and differentiation. Proliferative pre-B cells express very low levels of Bcl-2 whereas at the mature stage, resting B cells express Bcl-2 highly. In germinal centers, an important proliferation of B cells (ie centroblasts) occurs while these cells weakly express Bcl-2. Then, concomitantly to the rescue of germinal centers from apoptosis, Bcl-2 is induced on B cells (ie centrocytes). 9 In MM, the expression of Bcl-2 has been investigated only by immunohistological staining indicating that most of the patients tested express Bcl-2.
10,11 The expression of Bcl-2 has been also reported in the bone marrow plasma cells from healthy donors 11 but no quantitative comparison of this expression with the one observed in MM has been made.
In this study, we first determined the expression of Bcl-2 in malignant plasma cells from 49 MM patients in relation to the localisation of their tumor (bone marrow, peripheral blood and extramedullary sites) using Western blotting or flow cytometry. Then we compared this expression of Bcl-2 in malignant plasma cells with that of normal plasma cells from bone marrow and with peripheral blood plasma cells from reactive plasmacytosis. We present the first evidence that normal and malignant plasma cells express different levels of Bcl-2 according to their capacity to proliferate. Our results are interesting in understanding both the pathogenesis of MM and some of the mechanisms leading to the resistance of MM to standard treatment.
Patients and methods

Patients
Forty-nine patients with MM were studied. Their median age was 64 years (range 35-79 years). The male-to-female ratio was 0.56. A monoclonal serum Ig was found in 38 patients (IgG: 27; IgA: 11; biclonal: one patient). Ten patients had only free monoclonal light chains in urine. The : ratio was 1.7. Twenty-eight patients were previously untreated and 21 had progressive disease (ie relapse or primary treatment failure). In the latter, four patients presented with secondary plasma cell leukemia (PCL) and five with extramedullary involvement (EM) during disease progression: ascitis in patient No. 4, pleural effusion in patient Nos 1 and 2, a gastric plasmacytoma for patient No. 3 and a mammary plasmacytoma in patient No. 5. For the patients presenting an extramedullary involvement, no involvement either in the peripheral blood or in the bone marrow was observed at the same time. Four cases of reactive plasmacytosis were studied. In all cases, transient polyclonal circulating plasma cells were observed in the peripheral blood (from 7 to 50% plasma cells) in the context of viral infections. Diagnosis of reactive plasmacytosis was established both by cytological and flow cytometry plasma cell identification (intracellular kappa and lambda staining).
Reagents
B-B4 monoclonal antibody (mAb) (CD138) was a gift from Dr J Wijdenes (Diaclone Research, Besançon, France). Bcl-x rabbit affinity purified polyclonal antibodies and Bcl-2 mAb were purchased from Transduction Laboratories (Lexington, KY, USA) and Dako (Glostrup, Denmark), respectively.
Cell preparation and purification of plasma cells
Mononuclear cells were isolated by Ficoll-Hypaque density centrifugation from bone marrow aspirates or peripheral blood from patients with MM and healthy donors. The percentage of plasma cells was then determined by morphology on MayGrunwald-Giemsa smears and check by flow cytometry using two-color staining with anti-CD38 and B-B4 mAbs. Only samples with more than 8% plasma cells were used for purification. The purification of myeloma cells using anti-CD138 mAb (B-B4) was performed using a MACS separator (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were first labeled with anti-CD138 mAb then incubated with anti-IgG1 MACS microbeads before to proceed to magnetic separation on MS + separation column (Miltenyi Biotec). Only cell populations with a purity above 99% were used.
Immunoblot analysis of Bcl-2 and Bcl-x
Cells (2 × 10 6 ) were resuspended in 50 l of lysis buffer (10 mM Tris (pH 7.6) 150 mM NaCI 5 mM EDTA and 1% Triton X100) containing 2 mM PMSF and 2 g/ml aprotinine. Lysates were cleared by centrifugation at 12 000 g for 30 min at 4°C. Protein concentration was measured in each cell lysate using bicinchoninic acid (BCA protein assay; Pierce, Rockford, IL, USA). Fifteen micrograms of total proteins were loaded for each blot. The proteins were separated by 12.5% SDS-PAGE and transferred on to PVDF membranes. Blots were developed using a chemiluminescent detection system (ECL; Boehringer Mannheim, Meylan, France).
Flow cytometry analysis of Bcl-2 expression
For all patients, plasma cell identification was controlled by coexpression of CD138, CD38 and intracytoplasmic / in a three-color immunofluorescence assay. Apoptotic cells and cellular debris were excluded from the analysis by gating on the light scatter plot (R1). Careful analysis of the three-color stainings revealed that Ͼ99% of either -or -positive cells were viable plasma cells that coexpressed CD38 bright and CD138. The expression of CD138 has been shown to be restricted to viable plasma cells but lost on apoptotic plasma cells. 12 To study Bcl-2 expression we performed a double immunostaining, cytoplasmic light chain immunoglobulin (cIg) (anti-, anti-) vs Bcl-2 using an intracytoplasmic staining procedure. After two washes in PBS, mononuclear cells (3 × 10 5 per test) were permeabilized with a commercially available kit (Intraprep; Immunotech, Gagny, France) according to the manufacturer's instructions. Cells were then incubated with anti-/anti-Abs for 20 min at room temperature. After two washes in PBS, cells were stained for 20 min with Bcl-2-FITC antibody or with an IgG1-FITC control mAb in PBS 10% human AB serum. Samples were then analyzed by flow cytometry (FACSCalibur; Becton Dickinson, Le Pont de Claix, France). Apoptotic cells were excluded by gating on the light scatter region defined above (R1). Data analysis was done in cIg + /side scatter gate (R2) within the R1 cell population. In all cases, at least 4000 viable plasma cells were analyzed. The mean fluorescence ratio (MFR) of Bcl-2 was determined by dividing the geometric mean of fluorescence of Bcl-2 staining by that of the IgG1 control.
Labeling index of plasma cells
The labeling index of plasma cells was measured according to a modification of Carayon and Bord 13 using anti-bromodeoxyuridine (BrdU) mAb (BU5-1; Cymbus Bioscience, Euromedex, Souffelweyersheim, France) and analyzed by flow cytometry. The percentage of plasma cells in S phase was determined as the number of positive cells for BrdU staining within the population of -or -positive plasma cells. Briefly, 10 6 cells were incubated with or without (control) 50 mM BrdU for 2 h at 37°C in 5% CO 2 incubator, washed and permeabilized overnight in PBS containing 1% PFA and 0.01% Tween 20 at 4°C. After two washes, cells were treated for 30 min at 37°C with DNAse I (Sigma, St Quentin Fallavier, France). Cells were then washed in 0.5% Tween 20 PBS and labeled using PE-coupled anti-light chains mAbs for 30 min at room temperature. Following two washes, both control cells and the incorporated BrdU cells were stained with 10 l FITC-BU5-1 mAb in PBS supplemented with 0.5% Tween 20 and 20% AB serum for 45 min at room temperature. Then the cells were washed, resuspended in PBS, and analyzed immediately on a FACScalibur flow cytometer. For this purpose, data acquisition was performed on 50 000 cells and then on 10 000 live gated /-positive cells when the plasmacytosis represented less than 20% of total cells.
Results
Bcl-2 is expressed in the bone marrow malignant plasma cells from all patients with MM
The expression of Bcl-2 was determined by two-color immunofluorescence or by immunoblot analysis. For detection of Bcl-2 by two-color immunofluorescence, the plasma cells were identified by the expression of cytoplasmic immunoglobulin (cIg). As described in Materials and methods and as shown for one patient in Figure 1 , apoptotic cells were excluded from analysis by light scatter and cIg/SSC gates. Positive cIg cells were controlled to be viable plasma cells by their expression of CD138.
14 The immunoblot analysis required a highly purified population of malignant plasma cells. Also, only samples presenting a plasmacytosis greater than 8% were purified by an immunomagnetic method leading to a purity of at least 99%. In four patients, both methods were performed and gave similar results. This allowed us to study Bcl-2 expression independently of the method of analysis used (patient No. 6 is given as an example in Figure 2 ). The expression of Bcl-2 on bone marrow plasma cells was determined in 40 patients with MM. Representative immunoblots of eight patients and cytograms of two patients are outlined in Figure 2 . The results show that all malignant plasma cells from bone marrow express Bcl-2, and flow cytometry analysis allowed quantification of Bcl-2 expression with a mean fluorescence ratio (MFR) of 11.2 ± 5. Moreover, by Western blot analysis, anti-Bcl-x Abs were used as a control showing the 
Weak expression of Bcl-2 in malignant plasma cells from extramedullary sites but not from peripheral blood
Next, we compared Bcl-2 expression in malignant plasma cells from the peripheral blood of four patients with secondary PCL and from extramedullary sites of five patients. In the peripheral blood, Bcl-2 expression is similar to that observed in the bone marrow (MFR of Bcl-2 was 8.2 for one patient) (Figure 3b ). In contrast, the Bcl-2 expression is weak in all the five extramedullary sites tested. Indeed, myeloma cells from the two pleural effusions (EM Nos 1 and 2) as well as from the gastric plasmacytoma (EM No. 3) presented a low level of Bcl-2 by Western blotting (Figure 3a) . Furthermore, in myeloma cells from the ascitis, Bcl-2 is undetectable by Western blotting and the MFR in flow cytometry is 1.7. Finally, in extramedullary sites the MFR determined by flow cytometry ranged from 1.7 to 4.6 (2.9 ± 1.2). Of interest, the weak expression of Bcl-2 is not related to an absence of IL-6 in extramedullary sites since high levels of IL-6 are found in both ascitis and pleural effusion (0.5, 17, 100 ng/ml; unpublished personal data)
In conclusion, we found a high expression of Bcl-2 in all myeloma cells expanding within the bone marrow or circulating transiently in the peripheral blood but a weak expression of Bcl-2 in myeloma cells within extramedullary sites.
Plasma cells from normal bone marrow highly express Bcl-2 whereas plasma cells from reactive plasmacytosis express it very weakly
In order to compare Bcl-2 expression in myeloma cells to that of normal plasma cells, we performed flow cytometry analysis of the bone marrow of five healthy donors. As shown in Figure 4a , the whole population of normal plasma cells express high levels of Bcl-2 (MFR 10.5 ± 3). We next looked at the expression of Bcl-2 in reactive plasmacytosis. Reactive plasmacytosis was observed during the course of infectious diseases. These plasma cells were polyclonal, very proliferative and short-lived (personal data). By flow cytometry, plasma cells from these cases were found to express very weak levels of Bcl-2 (MFR 2.7 ± 0.4) (Figure 4a ). Moreover, in two cases, the percentage of plasma cells allowed us to purify them and to perform Western blotting analysis. As shown in Figure 4b , by Western blotting, Bcl-2 is almost undetectable in these plasma cells whereas again Bcl-x L is highly expressed.
Relationship of Bcl-2 expression in plasma cells to their proliferative rates and malignant status
The analysis of Bcl-2 expression indicates that high levels are found in both normal (MFR 10.5 ± 3) and malignant (MFR 11.2 ± 5) plasma cells from the bone marrow whereas low levels are found in malignant plasma cells from extramedullary sites (MFR 2.9 ± 1.2) and peripheral blood plasma cells from reactive plasmacytosis (MFR 2.7 ± 0.4) (Figure 5a ). Because it has been proposed that Bcl-2 is involved in cell cycle regulation, we studied the proliferation status of these different plasma cell populations. The labeling index of plasma cells was measured by flow cytometry, and the results are presented in Figure 5b . These results clearly demonstrated that there is an inverse correlation between the level of Bcl-2 and the proliferation rate regardless of their benign or malignant status. Indeed, we showed that malignant plasma cells from bone marrow or peripheral blood have a very weak labeling index (1.34% ± 0.9) but express high levels of Bcl-2. In con- trast, both malignant plasma cells from extramedullary sites and plasma cells from reactive plasmacytosis have a high labeling index (31% ± 11) and express very low levels of Bcl-2 (P Ͻ 0.01).
Discussion
This report clearly demonstrates that myeloma cells express high levels of Bcl-2 in vivo when they are localized in the bone marrow or transiently in the peripheral blood whereas they express it very weakly when they are expanding rapidly outside the bone marrow. Furthermore, by performing quantitative flow cytometric measurements of Bcl-2 on cIg + plasma cells we showed that high Bcl-2 expression in bone marrow myeloma cells reflects that found in their normal counterparts in the bone marrow environment. Finally, we demonstrated that Bcl-2 expression is inversely related to the proliferation state of the plasma cells regardless of their malignant status.
Bcl-2 expression has already been documented in human plasma cells when homing within the bone marrow, 11 but we have demonstrated here for the first time that malignant plasma cells express a normal level of Bcl-2, suggesting that this protein is not likely to be responsible for the emergence of malignant clones. In fact, this high expression is consistent with the notion that such plasma cells are non-dividing, fully differentiated and long-lived cells. 15, 16 However, the extremely long lifespan of plasma cells as recently demonstrated by Slifka et al 17 could provide an opportunity for myeloma cells to acquire further secondary genetic changes.
The role of Bcl-2 as an anti-apoptotic molecule is now well known. However, substantial progress have been made in elucidating its role as a regulatory molecule of the cell cycle. [4] [5] [6] [7] [8] To address such a question we analyzed the percentage of plasma cells in S phase and demonstrated that we could distinguish slowly proliferative plasma cells highly expressing Bcl-2 (Bcl-2 high ) from those highly proliferative weakly expressing Bcl-2 (Bcl-2 low ). Indeed, both normal and malignant plasma cells in the bone marrow are found as Bcl-2 high whereas malignant plasma cells expanding in extramedullary sites and peripheral blood plasma cells from reactive plasmacytosis are found as Bcl-2 low . These observations are in agreement with the recent demonstration that Bcl-2 can retard transition of B cells from the quiescent to the cycling state regardless of the differentiation stage. 18 In this way, the high expression of Bcl-2 in both normal and malignant bone marrow plasma cells may explain their slow proliferation whereas a weak expression of this protein may contribute in explaining the high turn-over observed in malignant plasma cells from extramedullary sites and in plasma cells from reactive plasmacytosis. Whereas this high proliferation rate in extramedullary sites has already been documented 19 little is known about this in reactive plasmacytosis. 20 However, the high rate of proliferation observed in reactive plasmacytosis is consistent with their fast appearance and disappearance during the clinical course of infectious diseases. Moreover, in extramedullary sites and in reactive plasmacytosis we observed elevated serum values of lactic dehydrogenase (results not shown) reflecting an important cells loss and suggesting a weaker resistance of these plasma cells to apoptosis. Again, one possible explanation for these observations could be the weak expression of Bcl-2. In a recent work, Ogata et al 21 suggested that myeloma cells from extramedullary sites can also be distinguished from bone marrow and peripheral blood myeloma cells by their ability to proliferate in response to IL-6, this response being associated with the Ras-dependent MAP kinase cascade activation. Again, these findings underline the high capacity of myeloma cells to proliferate in extramedullary sites. Moreover, it has been shown that Bcl-2 can interact with Raf-1, this interaction being important for the anti-apoptotic function of Bcl-2. 22 Also, Raf-1 appears as a key molecule for both the apoptotic and proliferative pathways. Altogether, these observations lead us to speculate that competition could exist between Ras and Bcl-2 family proteins for limiting amounts of Raf-1 as has already been proposed by Wang et al. 22 Although the events that regulate the expression of Bcl-2 are poorly understood, we can assume that: (1) the bone marrow environment is not involved in the regulation of Bcl-2 since peripheral blood and bone marrow malignant plasma cells express similar level of Bcl-2; (2) IL-6 is not responsible for the observed Bcl-2 regulation because high IL-6 levels are found both in MM and reactive plasmacytosis but also in pleural effusions and ascitis.
Our findings are in agreement with the observation of Winter et al 23 in intermediate-and high-grade non-Hodgkin's lymphoma, showing that there is an inverse relationship between Bcl-2 expression and proliferative activity. Moreover, the overexpression of Bcl-2 has often been associated with both the indolent nature of lymphoma and a better prognosis in some other types of cancer such as breast cancer and nonsmall cell lung carcinoma. 24, 25 Moreover, in MM, which is characterized by a very slow evolution, it has been reported that there is a trend toward an inverse correlation between Bcl-2 expression in bone marrow myeloma cells and patients survival. 26 Since most anti-cancer drugs target dividing cells, the high expression of Bcl-2 in bone marrow myeloma cells can participate in the resistance to treatment observed in MM. Although Bcl-2 can contribute both in resistance to apoptosis and chemoresistance, therapeutical intervention based on a down-regulation of Bcl-2 alone should be considered carefully. Indeed, our results suggest that such an intervention could favor S phase entry of plasma cells. Consequently, it will be judicious to use Bcl-2 antigens in combination with S and M phase-specific drugs already known to be efficient in the treatment of MM.
